Physician profile
Luis Diaz
NPI 1861966178
$1,058.20
in general payments reported to CMS, 2019-2025
11 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.08 · 2021: $21.61 · 2022: $184 · 2023: $204 · 2024: $25.59 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $170.36 | 2022-2023 | Xarelto |
| Axsome Therapeutics, INC. | $167.39 | 2025 | Symbravo |
| Abbvie INC. | $162.92 | 2021-2025 | Mavyret |
| E.R. Squibb & Sons, L.L.C. | $145.44 | 2025 | Zeposia |
| Tg Therapeutics, INC. | $129.01 | 2025 | |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Ponvory |
| Gilead Sciences, INC. | $58.56 | 2022-2023 | |
| Insmed, INC. | $33.56 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.59 | 2024 | Lifevest |
| Shire North American Group INC | $24.08 | 2019 | |
| Genentech USA, INC. | $16.29 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.